AI is slashing drug development costs by up to 70% and driving a projected $1 billion surge in new biopharma spending, but critics warn that no AI-discovered drug has yet received FDA approval, and the industry's notorious 90% failure rate may persist if human biological variability isn't properly addressed before …
Anthropic launches an internal drug discovery program targeting neglected diseases and unveils Claude Science, a new AI tool for drugmakers, positioning itself as a hands-on healthcare player alongside tech giants like Alphabet, Apple, and Amazon.
Google Cloud launches SandboxAQ's quantitative AI models and a new Gemini for Science suite, giving enterprise and research teams powerful tools to accelerate drug discovery, materials science, and semiconductor R&D by combining scientific numerical AI with Gemini's reasoning capabilities.
NVIDIA launches its Agent Toolkit, an open and modular platform empowering enterprises to build specialized AI agents with secure, customizable tools already achieving 98.5% alert accuracy in cybersecurity and accelerating drug discovery across major platforms like SAP, Siemens, and ServiceNow.
NVIDIA's BioNeMo Agent Toolkit is revolutionizing biomolecular research by doubling AI token efficiency and achieving a perfect 100% task completion rate, up from 57.1%, by packaging complex scientific models into autonomous, callable AI tools.
Biohub launches a groundbreaking open-source AI protein biology platform featuring three powerful tools that outperform AlphaFold 3 in antibody-antigen prediction, design cancer-targeting protein binders with up to 88% lab-validated hit rates, and make 6.8 billion protein sequences searchable to accelerate global scientific discovery.
Runway, now valued at $5.3 billion, is pivoting from AI filmmaking tools to building world models designed to simulate physical environments, targeting transformative applications in robotics, drug discovery, and climate modeling — but faces stiff competition from Google, OpenAI, and compute resource challenges.
Isomorphic Labs, the AI-driven drug discovery spinout from Google DeepMind, is closing in on a massive $2 billion funding round led by Thrive Capital, with Alphabet also joining the deal.
IBM, Cleveland Clinic, and Riken achieve a quantum computing breakthrough by simulating a 12,635-atom protein complex — a massive leap from just 10 atoms in October 2024 — unlocking powerful new possibilities for drug discovery and disease treatment.
MIT and IBM are launching the MIT-IBM Computing Research Lab, expanding their seven-year AI collaboration into quantum and hybrid computing systems to tackle real-world challenges like drug discovery, weather prediction, and financial forecasting.